Cancer Detection at Your Fingertips: Bioholo-tomography Promises Enormous Growth Potential, According to Frost & Sullivan

LONDON, May 25, 2010 - As the potential cancer population increases, an effective long-term
solution for early cancer detection needs to be found. In some areas of the
world, cancer incidence is growing by 3 per cent per annum, and the cost of
cancer care is a ticking time bomb for global healthcare expenditure.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

According to latest research from Frost & Sullivan
(www.frost.com), a novel approach to cancer diagnostics is on the
rise, capable of targeting a specific organ or region of interest and
enabling refined and high-resolution image capture and analysis.

Bioholo-tomography (BHT) is a technology which acquires holographic
information for diagnostic purposes on any affected region of the body using
only surface readings. This low-cost imaging technique does not require any
exposure to ionizing radiation and is the technology behind a device called
the Cancer Instant Detector (CID) developed by Advanced Bioresearch &
Technology Ltd (ABR), together with the Center of Bioholography Ltd.,
Georgia.

Detection of cancer at its earliest possible stages remains the best
strategy for improving cancer patients' quality of life and reducing cancer
deaths. Yet the majority of cancers in early development stages have no
obvious symptoms and may not be detected unless an individual arrives for a
routine check-up at the physician's office or as part of cancer screening
programmes.

"The CID incorporates a simplified and portable device that can rapidly
capture diagnostic-quality information capable of revealing both
physiological anomalies," explains Research Analyst Prasanna Vadhana Kannan
from Frost & Sullivan's Technical Insights Group, who have been tracking the
developments of the technology since 2005. "Through CID, a full-body scan is
accomplished by non-invasive examination of the induced emissions from the
fingertips."

Using the CID as a detection tool, the probability of cancer, its
location within a pre-defined body segment and the degree of aggressiveness
can be determined and displayed within seconds.

"The entire non-invasive procedure with a CID lasts only a few minutes
and is harmless for patients, operators and the environment," says Dr. Marina
Shaduri, founder of the Center of Bioholography in Tbilisi, Georgia.

The newly-developed imaging technique has demonstrated significant
degrees of reliability and validity both in everyday practice and in a
controlled clinical study. The device can potentially be used anywhere in the
world for mass-screening and for monitoring of at-risk patients or to
evaluate patients who have undergone treatment.

"Any doctor would benefit from this new option of diagnostics, since the
CID would detect cancer at early stages in a user-friendly way and it would
also determine its location in a defined body segment as well as the
aggressiveness of pathology," continues Dr. Shaduri.

With technologies like Bioholo-tomography that are based on the
evaluation of the entire human body, the search for proper therapies
targeting cancer might be accelerated tremendously, since the development and
testing of new drugs, including cancer drugs, would be less costly or
time-consuming. The technology of recording and analyzing biological
holograms provides a new kind of valuable information on the human body.

"By using the CID in association with established imaging modalities,
unnecessary biopsies and surgery could be avoided. Such a modality might be
used for both the detection of cancer and the monitoring of a patient's
condition in order to evaluate the efficiency of any therapeutic procedure or
drug," concludes analyst Prasanna Kannan.

For further information on Bioholo-tomography, the CID or investment
opportunities in Advanced Bioresearch & Technology Ltd, please contact Katja
Feick at katja.feick@frost.com.

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from more than 40 offices on six continents. To join our Growth
Partnership, please visit www.frost.com.

Contact:

    Katja Feick
    Corporate Communications - Europe
    P: +49(0)69-7703343
    E: katja.feick@frost.com

    www.frost.com
    Twitter: twitter.com/frost_sullivan

Katja Feick, Corporate Communications - Europe, Frost & Sullivan, +49(0)69-7703343, katja.feick at frost.com